Genetic testing in oncology: 5 things payers should knowAs genomics continues to evolve, here are five things to know about genetic testing and counseling.
Payments to specialists could yo-yo under MIPSAvalere conducted an analysis to assess the effect of MIPS. Here are the surprising results.
Four ways the genomic data commons will advance cancer careA new cancer database, the Genomic Data Commons, aims to make research more accessible
Proposed Medicare Part B rule would cut payments for some drugsNew analysis finds proposed Medicare payment changes for physician-administered drugs would reduce reimbursement for those that cost more than $480 per day in 2016. Seven of the 10 drugs that constitute the largest reduction in reimbursement are used to treat cancer.
Are we ready to assess the value of cancer drugs?A presenter at the AMCP Annual Meeting examines two different tools released by ASCO and NCCN and how a managed care organization utilizes these tools in the formulary review process.
Value-based treatments, discoveries address top cancers
Achieving balance: Providing high-value cancer care
Achieving balance: Providing high-value cancer careHow plans can achieve the right balance between cost and outcomes
Oncologists not prescribing expensive cancer drugsIn the latest controversy over the high cost of certain prescription medications, a recent Reuters article said that more oncologists won’t prescribe expensive drugs.
Personalized treatments for lung cancer underused: International surveyDespite the majority of newly diagnosed advanced non-small cell lung cancer (NSCLC) patients being tested for genetic mutations, a gap still exists for providing a personalized treatment plan for patients. An international survey, sponsored by Boehringer Ingelheim, found that 60% of US oncologists do not determine their treatment decision based on patient’s genetic mutation subtype, compared with 50% in Canada and 23% in Asia.
Single-payer healthcare system endorsed by oncologistsTwo oncologists are calling on fellow oncologists and the American Society of Clinical Oncology (ASCO) to support a single-payer healthcare system, according to an article published in the January issue of the Journal of Oncology Practice.